文献速递脑血管病

成功再灌注通过梗死增长和脑水肿介导临床获益:EXTEND-IA试验与SELECT前瞻性队列的汇总患者水平分析

Mediation of Successful Reperfusion Effect through Infarct Growth and Cerebral Edema: A Pooled, Patient-Level Analysis of EXTEND-IA Trials and SELECT Prospective Cohort.
PubMed 文献 · Ann Neurol · 2023-01-17

该研究汇总EXTEND-IA试验与SELECT研究共665例患者,其中542例(81.5%)实现成功再灌注;中介分析显示梗死增长和脑中线移位分别解释成功再灌注对功能结局效应的45%和34%,二者纳入模型后成功再灌注与功能结局的关联不再显著。作者认为约80%的再灌注获益由这两个中介因素介导,但需进一步研究确认。

要点

  • 成功再灌注与梗死增长减少(β=-1.19,95%CI -1.51至-0.88,p<0.001)及中线移位减少(校正OR=0.36,95%CI 0.23-0.57,p<0.001)相关。
  • 成功再灌注与功能结局改善相关(校正共同OR=2.68,95%CI 1.86-3.88,p<0.001),加入梗死增长与中线移位后不再显著(校正共同OR=1.39,95%CI 0.95-2.04,p=0.094)。
  • 梗死增长和中线移位分别解释成功再灌注效应的45%和34%。

核心结论

  • 在汇总患者水平队列的中介分析中,成功再灌注对功能结局的效应约80%通过梗死增长减少和脑水肿(中线移位)减少介导。
  • 作者指出需进一步研究确认上述发现、寻找其他中介因素以解释残余效应,并识别新的治疗靶点以进一步增强再灌注获益。

研究设计与样本

  • 汇总患者水平分析,纳入EXTEND-IA试验与SELECT前瞻性队列,共665例符合条件患者,其中542例(81.5%)实现成功再灌注。
  • 采用中介分析框架,评估梗死增长与脑水肿(中线移位)对成功再灌注(改良脑缺血溶栓分级≥2b)与功能结局(改良Rankin量表分布)关联的中介效应。
  • 另评估梗死增长介导成功再灌注对中线移位效应的替代通路。

主要发现

  • 梗死增长中位数12.3ml(四分位距1.8-48.4),中线移位中位数0mm(四分位距0-2.2)。
  • 249例(37%)出现≥1mm的中线移位,其中移位中位数2.75mm(四分位距1.89-4.21)。
  • 成功再灌注与梗死增长减少相关(β=-1.19,95%CI -1.51至-0.88,p<0.001),与中线移位减少相关(校正比值比=0.36,95%CI 0.23-0.57,p<0.001)。
  • 成功再灌注与功能结局改善相关(校正共同比值比=2.68,95%CI 1.86-3.88,p<0.001),模型中同时加入梗死增长与中线移位后该关联不再显著(校正共同比值比=1.39,95%CI 0.95-2.04,p=0.094)。
  • 梗死增长和中线移位分别解释成功再灌注效应的45%和34%;考虑替代假设的分析结果一致。

局限性

  • 作者指出需进一步研究以确认本研究发现。
  • 作者指出需进一步研究以发现其他中介因素来解释成功再灌注的残余效应。
  • 作者指出需进一步研究以识别新的治疗靶点来进一步增强再灌注获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Reperfusion therapy is highly beneficial for ischemic stroke. Reduction in both infarct growth and edema are plausible mediators of clinical benefit with reperfusion. We aimed to quantify these mediators and their interrelationship. METHODS: In a pooled, patient-level analysis of the EXTEND-IA trials and SELECT study, we used a mediation analysis framework to quantify infarct growth and cerebral edema (midline shift) mediation effect on successful reperfusion (modified Treatment in Cerebral Ischemia ≥ 2b) association with functional outcome (modified Rankin Scale distribution). Furthermore, we evaluated an additional pathway to the original hypothesis, where infarct growth mediated successful reperfusion effect on midline shift. RESULTS: A total 542 of 665 (81.5%) eligible patients achieved successful reperfusion. Baseline clinical and imaging characteristics were largely similar between those achieving successful versus unsuccessful reperfusion. Median infarct growth was 12.3ml (interquartile range [IQR] = 1.8-48.4), and median midline shift was 0mm (IQR = 0-2.2). Of 249 (37%) demonstrating a midline shift of ≥1mm, median shift was 2.75mm (IQR = 1.89-4.21). Successful reperfusion was associated with reductions in both predefined mediators, infarct growth (β = -1.19, 95% confidence interval [CI] = -1.51 to -0.88, p < 0.001) and midline shift (adjusted odds ratio = 0.36, 95% CI = 0.23-0.57, p < 0.001). Successful reperfusion association with improved functional outcome (adjusted common odds ratio [acOR] = 2.68, 95% CI = 1.86-3.88, p < 0.001) became insignificant (acOR = 1.39, 95% CI = 0.95-2.04, p = 0.094) when infarct growth and midline shift were added to the regression model. Infarct growth and midline shift explained 45% and 34% of successful reperfusion effect, respectively. Analysis considering an alternative hypothesis demonstrated consistent results. INTERPRETATION: In this mediation analysis from a pooled, patient-level cohort, a significant proportion (~80%) of successful reperfusion effect on functional outcome was mediated through reduction in infarct growth and cerebral edema. Further studies are required to confirm our findings, detect additional mediators to explain successful reperfusion residual effect, and identify novel therapeutic targets to further enhance reperfusion benefits. ANN NEUROL 2023;93:793-804.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Sarraj A, Pujara DK, Churilov L, et al. Mediation of Successful Reperfusion Effect through Infarct Growth and Cerebral Edema: A Pooled, Patient-Level Analysis of EXTEND-IA Trials and SELECT Prospective Cohort. Ann Neurol. 2023. PMID: 36571388. doi:10.1002/ana.26587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。